Tilray Brands Reports $217.5M Q2 Revenue, 36% Surge in International Medical Cannabis Sales
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5h ago
0mins
Source: Fool
- Record Revenue: Tilray Brands reported a record revenue of $217.5 million for Q2 of fiscal 2026, reflecting a modest 3% year-over-year increase, which, while not impressive, indicates resilience in a challenging market environment that may instill some investor confidence.
- International Sales Surge: The company achieved a 36% increase in international medical cannabis sales, highlighting Tilray's potential for global market expansion, although overall growth remains lackluster, this strong performance could support future strategic initiatives.
- Improved Operating Loss: Tilray's operating loss narrowed to $22.3 million this quarter from $42.2 million a year ago, primarily due to reduced restructuring costs and amortization expenses, laying a foundation for improved profitability moving forward.
- Uncertain Market Outlook: Despite short-term gains from acquisitions and market excitement, the lack of consistent organic growth raises caution among investors regarding Tilray's long-term prospects, suggesting that significant volatility may persist in the stock's performance.
Analyst Views on TLRY
Wall Street analysts forecast TLRY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TLRY is 9.57 USD with a low forecast of 8.50 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 8.750
Low
8.50
Averages
9.57
High
10.00
Current: 8.750
Low
8.50
Averages
9.57
High
10.00
About TLRY
Tilray Brands, Inc. is a global lifestyle and consumer packaged goods company. The Company operates through four segments: Cannabis operations, Distribution business, Beverage alcohol business and Wellness business. The Cannabis operations, which encompasses the production, distribution, sale, co-manufacturing and advisory services of both medical and adult-use cannabis. The Beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products. The Distribution operations, which encompasses the purchase and resale of pharmaceuticals products to customers. The Wellness products, which encompasses hemp foods and cannabidiol (CBD) products. The Company offers a portfolio of adult-use brands and products and expands its portfolio to include new cannabis products and formats. Its brands include Good Supply, RIFF, Broken Coast, Solei, Canaca, HEXO, Redecan, Original Stash, Hop Valley, Revolver, Bake Sale, XMG, Mollo, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
